Myelodysplastic Syndromes (MDS)
50
12
16
19
Key Insights
Highlights
Success Rate
79% trial completion
Published Results
11 trials with published results (22%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
10.0%
5 terminated out of 50 trials
79.2%
-7.3% vs benchmark
6%
3 trials in Phase 3/4
58%
11 of 19 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 19 completed trials
Clinical Trials (50)
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes
Asia Myelodysplastic Syndrome (MDS) Registry
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
The National Myelodysplastic Syndromes (MDS) Study
CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial
Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT
Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Cord Blood Transplant in Adults With Blood Cancers
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept
Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies
Evaluation of Response to Biosimilar Erythropoietin Alfa Therapy in Anemic Patients With Myelodysplastic Syndrome